

Boehringer Ingelheim puts focus on novel therapies for retinal diseases

24 September 2019 | News

Partners with Inflammasome Therapeutics



German player **Boehringer Ingelheim** and US based **Inflammasome Therapeutics Inc.** (**Inflammasome**) have announced that they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases.

By combining **Inflammasome's** unique intravitreal (IVT) drug delivery technologies with **Boehringer Ingelheim's** compounds from its retinal disease pipeline portfolio, **Boehringer Ingelheim** aims to develop novel therapies for retinal diseases.

Boehringer Ingelheim takes a holistic approach in the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. The company has built a comprehensive pipeline portfolio of next generation therapy approaches in various stages of development up to Phase 2 in macular degeneration, diabetic retinal diseases and beyond. **Inflammasome's** novel delivery technology using a long-acting degradable IVT implant complements this portfolio.

Inflammasome is entitled to receive up to \$160 million in up-front, research and development support and milestone gated development payments as well as tiered royalties based on future commercial sales of developed products and other milestones due on commercialization.